BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Average Recommendation of "Moderate Buy" by Analysts

Key Points

• Analysts have a “Moderate Buy” consensus on BioMarin, with 14 buy, two strong-buy, six hold, and one sell rating among 23 analysts. The average 12-month price target is $89.17.
• BioMarin exceeded quarterly expectations, reporting $1.20 in EPS versus $0.95 estimated and $989.71 million in revenue, up 20% year over year.
• The stock opened at $66.53, near its 52-week high of $70.98, while institutional investors own 98.71% of outstanding shares.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Free Report) has been given a consensus rating of "Moderate Buy" by the twenty-three research firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, six have given a hold recommendation, fourteen have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $89.1739.

BMRN has been the subject of a number of analyst reports. UBS Group set a $88.00 price target on BioMarin Pharmaceutical in a research report on Wednesday, August 26th. Morgan Stanley boosted their price objective on BioMarin Pharmaceutical from $119.00 to $124.00 and gave the company an "overweight" rating in a research note on Friday, August 7th. Citigroup increased their target price on shares of BioMarin Pharmaceutical from $75.00 to $76.00 and gave the stock a "buy" rating in a report on Thursday, July 16th. Weiss Ratings upgraded shares of BioMarin Pharmaceutical from a "sell (d)" rating to a "sell (d+)" rating in a research note on Thursday. Finally, HC Wainwright lifted their price target on shares of BioMarin Pharmaceutical from $59.00 to $60.00 and gave the company a "neutral" rating in a report on Monday, August 31st.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Parkside Financial Bank & Trust raised its holdings in BioMarin Pharmaceutical by 70.3% during the second quarter. Parkside Financial Bank & Trust now owns 453 shares of the biotechnology company's stock valued at $26,000 after acquiring an additional 187 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of BioMarin Pharmaceutical during the second quarter worth about $39,000. CIBC Private Wealth Group LLC grew its position in shares of BioMarin Pharmaceutical by 38.2% during the fourth quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company's stock worth $39,000 after purchasing an additional 179 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in BioMarin Pharmaceutical during the 3rd quarter valued at approximately $40,000. Finally, Parallel Advisors LLC raised its stake in BioMarin Pharmaceutical by 62.2% during the 3rd quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company's stock valued at $42,000 after purchasing an additional 295 shares during the period. Hedge funds and other institutional investors own 98.71% of the company's stock.

BioMarin Pharmaceutical Trading Up 0.2%

Shares of BioMarin Pharmaceutical stock opened at $66.53 on Friday. The company's fifty day simple moving average is $62.58 and its 200-day simple moving average is $58.37. The stock has a market capitalization of $12.88 billion, a PE ratio of 179.81, a P/E/G ratio of 0.48 and a beta of 0.24. BioMarin Pharmaceutical has a 1-year low of $49.26 and a 1-year high of $70.98. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.39 and a quick ratio of 1.32.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, topping the consensus estimate of $0.95 by $0.25. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%.The firm had revenue of $989.71 million during the quarter, compared to analyst estimates of $932.03 million. During the same period in the prior year, the business posted $1.44 EPS. BioMarin Pharmaceutical's revenue was up 20.0% on a year-over-year basis. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. As a group, equities analysts anticipate that BioMarin Pharmaceutical will post 4.1 earnings per share for the current year.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company's commercial portfolio includes several approved therapies targeting inherited disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source